Mark Elliott Boulding sold $280k of PTCT
EXEC. VP AND CLO at PTC THERAPEUTICS, INC.. 3,540 shares at an average of $78.97, traded May 8, 2026, filed May 12, 2026.
Score components
- +15RoleOfficer
- +14Trade size$280k at market
- 0Share of holdings soldSold 3.3% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -0.4%, 3m -1.8%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001578852-26-000014, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 8, 2026 | MOption exercise Common Stock10b5-1 | +2,740 | $46.54 | $128k | 107,952 | May 12, 2026 |
| May 8, 2026 | SOpen-market sale Common Stock10b5-1 | -840 | $78.23 | $66k | 107,112 | May 12, 2026 |
| May 8, 2026 | SOpen-market sale Common Stock10b5-1 | -1,900 | $79.31 | $151k | 105,212 | May 12, 2026 |
| May 8, 2026 | MOption exercise Common Stock10b5-1 | +800 | $46.54 | $37k | 106,012 | May 12, 2026 |
| May 8, 2026 | SOpen-market sale Common Stock10b5-1 | -200 | $78.00 | $16k | 105,812 | May 12, 2026 |
| May 8, 2026 | SOpen-market sale Common Stock10b5-1 | -600 | $79.28 | $48k | 105,212 | May 12, 2026 |
| May 8, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,740 | $0.00 | $0 | 42,260 | May 12, 2026 |
| May 8, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -800 | $0.00 | $0 | 41,460 | May 12, 2026 |
Related signals
Other insiders at PTC THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $158k 2,500 shares | -0% | |
| 6Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $133k 2,073 shares | -2% | |
| 27Weak | PTC THERAPEUTICS, INC. | Glenn Steele Jr Md Phd director | $782k 12,000 shares | -35% | |
| 28Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $1.3M 20,000 shares | -2% | |
| 20Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $1.4M 20,000 shares | -1% | |
| 14Weak | PTC THERAPEUTICS, INC. | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | $693k 8,130 shares | -13% | |
| 23Weak | PTC THERAPEUTICS, INC. | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | $2.3M 26,283 shares | -43% | |
| 23Weak | PTC THERAPEUTICS, INC. | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | $1.9M 23,749 shares | -28% | |
| 11Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $823k 10,462 shares | -9% | |
| 0Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $203k 2,812 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.